Oncology company Lucence and Ghana-based cancer research firm Yemaachi Biotech are collaborating on a study aimed at characterizing the genomics of breast cancer in women of African descent.
The trial, called The Liquid Biopsy for Detection of Actionable Genomic Mutations in Women of African Descent with Advanced Breast Cancer (AMBER), will prospectively explore the utility of Lucence's LiquidHallmark cell-free DNA (cfDNA) liquid biopsy assay in identifying actionable genetic mutations in metastatic breast cancer patients in Ghana.
Specifically, the study will examine actionable mutations in genes including PIK3CA, BRCA1, BRCA2, and ESR1 in treatment-naive metastatic breast cancer patients recruited from Cape Coast Teaching Hospital. The goal is to identify and evaluate the mutation profiles of cancers in Ghanaian women, accordance to Lucence and Yemaachi.
